Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?
From Yahoo Finance: 2025-05-11 17:01:00
Jim Simons’ Renaissance Technologies is known for its groundbreaking success in quantitative trading. The Medallion hedge fund, despite being closed to outside investors, has maintained an impressive annual return of 31.5%. Simons’ worth at his death was $31.4 billion, owing to the Medallion Fund’s strong market performance.
Renaissance Technologies had a stellar 2024 performance, with their funds continuing to perform well in 2025. The Renaissance Institutional Diversified Alpha Fund gained 9.05% in February, building on its 2024 return of 15.6%. The Renaissance Institutional Equities Fund rose 11.85% in the first two months of 2025. Both funds employ a mix of individual stock positions, stock index futures, and options.
United Therapeutics Corporation (UTHR) is a biotechnology company developing organ replacements and treatments for organ disorders. Their primary medications, Tyvaso, Orenitram, and Remodulin, target patients, hospitals, and specialty pharmacies. UTHR exceeded market expectations in Q1 2025, reporting EPS of $6.63 and record revenue of $794.4 million, driven by strong demand for treprostinil products.
TD Cowen reiterated its Buy rating for United Therapeutics Corporation, citing a stable $400 price target. Management expressed confidence in the drug Tyvaso PH-ILD’s potential to treat Idiopathic Pulmonary Fibrosis. UTHR ranks 2nd on the list of best stocks according to Jim Simons’ Renaissance Technologies but may not offer as high potential returns as certain AI stocks.